MSB Provides Q3 Operational Highlights and Financial Results
Filed with ASX · · 9 pages · English
In the deck
Earlier from Mesoblast
- Third Quarter Financial Results On Form 6-K
- Successful Interim Analysis in Phase 3 Heart Failure Trial
- Mesoblast Receives A$3.7m From Aus Govt For R&D
- FDA Clears Heart Disease Trial At Boston Childrens Hospital
- Process Initiated For CHF P3 Interim Analysis
Later from Mesoblast
- Mesoblast RA Results Presented At EULAR Congress
- Positive Results of MSB Therapy in Osteoarthritis Published
- Potential For Accelerated Market Entry In Advanced CHF
- Fully Underwritten A$50.7 Million Entitlement Offer
- Underwritten A$50.7M Raise Closes Institutional Allocation
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast